A549-Luc Cells
USD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | A549-Luc is a genetically engineered derivative of the human lung adenocarcinoma cell line A549, modified to stably express the firefly luciferase reporter gene. The parental A549 cell line originates from a lung carcinoma of an adult patient and is widely used as a model for non-small cell lung cancer (NSCLC), particularly adenocarcinoma. A549 cells exhibit epithelial morphology and harbor key molecular features relevant to lung cancer biology, including mutations in KRAS and alterations in pathways regulating proliferation, metabolism, and response to oxidative stress. The luciferase-expressing variant retains these intrinsic characteristics while enabling bioluminescent detection. The incorporation of the luciferase gene allows for sensitive, non-invasive quantification of viable cells through bioluminescence imaging following administration of a luciferin substrate. This enables real-time monitoring of cell proliferation, tumor growth, and therapeutic response in both in vitro assays and in vivo xenograft models. The emitted light signal correlates with metabolically active cell number, making A549-Luc particularly suitable for longitudinal studies of tumor kinetics, metastasis, and drug efficacy. Stable integration ensures sustained reporter expression, although signal intensity may vary depending on clone selection and experimental conditions. A549-Luc maintains the biological behavior of the parental A549 line, including its utility in studies of lung cancer progression, inflammation, and response to chemotherapeutic or targeted agents. The addition of a luciferase reporter significantly enhances experimental flexibility, supporting high-throughput drug screening, in vivo imaging, and quantitative assessment of tumor burden over time. As such, A549-Luc is a valuable tool for translational lung cancer research and preclinical evaluation of novel therapeutic strategies. |
|---|---|
| Organism | Human |
| Tissue | Lung |
| Disease | Lung adenocarcinoma |
Characteristics
| Age | 58 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Growth properties | Adherent |
Regulatory Data
| Citation | A549-Luc (Cytion catalog number 305648) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_J242 |
| GMO Status | GMO-S1: This human A549 lung carcinoma line contains a lentiviral-Luc reporter construct enabling bioluminescent monitoring of tumor response. This classification applies only within Germany and may differ elsewhere. |
Biomolecular Data
| Mutational profile | Mutation: p.Gly12Ser, Homozygous; Mutation: p.Gln37Ter, Homozygous |
|---|
Handling
| Freeze medium | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
|---|---|
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |